Molecular Interactions Between Nattokinase and Heparin/Glycosaminoglycans

This in vitro biochemical study characterized the molecular interaction between nattokinase and heparin — as well as other glycosaminoglycans (GAGs) — using surface plasmon resonance, NMR, and competitive binding assays.

Nattokinase was found to bind heparin with moderate affinity (approximately 250 nM Kd), requiring a minimum oligosaccharide chain length of six sugar units and specific sulfation patterns. Nattokinase competed with antithrombin for heparin binding sites, and also disrupted heparin’s binding to growth factors (FGF-2), suggesting that nattokinase’s biological effects may extend to disruption of heparin-dependent physiological signaling beyond direct fibrinolysis.

The finding that nattokinase is a heparin-binding protein is mechanistically novel — it means that in the presence of heparin (endogenous at vascular surfaces or exogenous therapeutically), nattokinase’s behavior may be modified by GAG binding. Whether this binding relationship has any in vivo significance for nattokinase’s proposed cardiovascular effects is speculative.

This study represents a level of mechanistic detail that is unusual for a nutraceutical — most supplement research does not achieve this degree of molecular characterization. However, the gap between detailed in vitro binding studies and clinical outcome evidence remains vast for nattokinase. The heparin-binding property does not directly support any specific cardiovascular clinical application.

We rate the evidence limited. An in vitro biochemical study characterizing nattokinase’s heparin-binding properties at the molecular level — technically sophisticated but distant from any clinical cardiovascular application without human pharmacokinetic and outcome data.